Cryoport, Inc. · NASDAQ:CYRX
Cryoport — Investor Presentation (January 2021)
26 slides from Cryoport's investor presentation, Jan 19, 2021
Slide 1: Cryoport CYRX: NASDAQ
© 2021 Cryoport, Inc. All Rights Reserved CYRX: NASDAQ
Slide 2: Forward Looking Statements
© 2021 Cryoport, Inc. All Rights Reserved Forward Looking Statements Statements in this presentation and statements made orally during this presentation are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projections, plans
Slide 3: Cryoport – A Trusted Partner to Life Sciences Companies
© 2021 Cryoport, Inc. All Rights Reserved Life sciences company focused on providing mission critical, proprietary temperature - controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature - controlled state such as: CAR
Slide 4: A Global Leader of Temperature-Controlled Supply Chain Solutions for the Life Sciences
© 2021 Cryoport, Inc. All Rights Reserved A Global Leader of Temperature - Controlled Supply Chain Solutions for the Life Sciences The Industry’s Most Trusted Provider of Temperature - Controlled Supply Chain Solutions for Temperature - Sensitive Life Sciences In dustry ~45% of all Phase III Regener
Slide 5: Attractive High-Growth Regenerative Medicine Market Driving Expected Demand
© 2021 Cryoport, Inc. All Rights Reserved Attractive High - Growth Regenerative Medicine Market Driving Expected Demand Patients Treated per Year in Trials of Commercially Approved Therapies Therapies Approved by Scenario # of patients treated in - year with C> therapies (000’s) # new therapies ap
Slide 6: Cryoport Grows with Dynamic and Expanding TAM
© 2021 Cryoport, Inc. All Rights Reserved Cryoport Grows with Dynamic and Expanding TAM Regenerative Medicine FY 2020 Cell & Gene Therapy Growing 35 – 40%+ Active Oncology Clinical Trials Total Global Financing Raised Gene, Cell & Tissue - Based therapeutic companies globally Active Global Clinical
Slide 7: Cryoport Systems' Differentiators
© 2021 Cryoport, Inc. All Rights Reserved Cryoport Systems’ Differentiators • Fully Integrated System, Processes and Equipment • Life Sciences Industry’s Most Advanced Informatics Platform • 24/7/365 Personnel • Full Chain of Compliance ® Scientifically Engineered Shippers Near Real - time Monitorin
Slide 8: Cryoport Express Shippers are Validated for Safe, Effective and Efficient Transport
© 2021 Cryoport, Inc. All Rights Reserved Cryoport Express ® Shippers are Validated for Safe, Effective and Efficient Transport 8 Cryoport Express ® Shippers are designed to be non - hazardous and capable of maintaining temperatures of under - 150 C for up to 10 days under dynamic conditions Smartpa
Slide 9: Minimizing Risk and Maximizing Success: Chain of Compliance
© 2021 Cryoport, Inc. All Rights Reserved Minimizing Risk and Maximizing Success CHAIN OF COMPLIANCE ® Traceability of the Equipment and Processes Supporting each Client’s or Patient’s Therapy Chain of Custody Traceability of the Custody of each Client’s or Patient’s Therapy Chain of Condition Trace
Slide 10: Clinical Trial Funnel to Commercial Biopharma Revenue
© 2021 Cryoport, Inc. All Rights Reserved Clinical Trial Funnel to Commercial Biopharma Revenue 10 69 Phase III Clinical Trials Supported by Cryoport, 5 Commercial Therapies Trials 0 100 200 300 400 500 600 Americas EMEA APAC x 92 additional new trials (net) added in 2020 x 528 clinical trials in ag
Slide 11: Recent Acquisitions Provide a More Integrated End-to-End Supply Chain Solution
© 2021 Cryoport, Inc. All Rights Reserved 11 With the company's recent acquisitions, Cryoport provides a more integrated, end - to - end supply chain solution set to cell and gene therapy clients as well as the broader life sciences industry Raised $275MM in preferred and common stock with Blackston
Slide 12: CRYOPDP – Uniquely Positioned Global Temperature-Controlled Supply Chain Network
© 2021 Cryoport, Inc. All Rights Reserved CRYOPDP – Uniquely Positioned Global Temperature - Controlled Supply Chain Network to Support the Life Sciences Industry 25 Years of Service Serving 150 countries Headquarters: Paris, France 230 employees in 12 countries CRYOPDP is the third largest specialt
Slide 13: Global Scale of a Unified Cryoport and CRYOPDP Network
© 2021 Cryoport, Inc. All Rights Reserved Global Scale of a Unified Cryoport and CRYOPDP Network Best Clinical Trial Logistics Provider WINNER 1 o Cryoport Locations CRYOPDP Locations MVE Biological Solutions Locations 13
Slide 14: MVE Biological Solutions Overview
© 2021 Cryoport, Inc. All Rights Reserved MVE Biological Solutions Overview Over 50 years of setting the standard for cryogenic storage A global leader of cryogenic freezers and dewars in the life sciences industry Headquarters: Ball Ground, GA 244 employees globally MVE Biological Solutions is a le
Slide 15: Current Cell & Gene Therapy Pipeline Driving Revenue Growth
© 2021 Cryoport, Inc. All Rights Reserved Current Cell & Gene Therapy Pipeline Driving Revenue Growth • Seven Cryoport supported Marketing Authorization Applications (MAA’s) or Biologic License Applications (BLA’s) were filed in 2020 • Anticipate up to 23 MAA or BLA submissions for Cryoport - suppor
Slide 16: COVID-Support Clinical Trials Supported by Cryoport
© 2021 Cryoport, Inc. All Rights Reserved COVID - 19 Support Clinical Trials Supported by Cryoport 18 trials 6 trials 5 trials Total Clinical Trials 29 trials As of 12/31/2020, Cryoport supported 29 separate clinical trials across our business units, including a leading COVID - 19 vaccine candidate
Slide 17: Financial Overview
© 2021 Cryoport, Inc. All Rights Reserved Financial Overview
Slide 18: Pro Forma Income Statement
© 2021 Cryoport, Inc. All Rights Reserved Pro Forma Income Statement 18 Cryoport , Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Statements of Operations Year Ended December 31, 2019 in MM Cryoport Pro Forma CRYOPDP Pro Forma MVE Pro Forma Combined Revenues 33.9 47.4 81.9 163.2 Cost o
Slide 19: Immediately Accretive Pro Forma Adjusted EBITDA Profile
© 2021 Cryoport, Inc. All Rights Reserved Immediately Accretive Pro Forma Adjusted EBITDA Profile 19 (4.0) 1.6 24.3 21.9 (10.0) 0.0 10.0 20.0 30.0 (10) 0 10 20 30 9-Month Trailing Pro Forma $MM 9 Month Trailing Adj. EBITDA (as of 9/30/20) (1) FY 2019 Adj. EBITDA (1) $MM 2.0 1.5 31.4 34.9 0.0 20.0 40
Slide 20: Expanding Tools and Solutions for the Life Sciences: Cryoport Family of Companies
© 2021 Cryoport, Inc. All Rights Reserved Expanding Tools and Solutions for the Life Sciences Synergies – Cryoport Family of Companies – Separate Responsibility – Intercompany agreements and sales incentives Cryoport, Inc. (NASDAQ: CYRX) 20
Slide 21: Summary
© 2021 Cryoport, Inc. All Rights Reserved Summary 21 End - to - end solutions platform offering fully integrated temperature controlled supply chain solutions for the life sciences Well positioned to take advantage of the growing needs in the cell & gene therapy market A market leader with long - te
Slide 22: Management
© 2021 Cryoport, Inc. All Rights Reserved Management 22 Jerrell Shelton , Chief Executive Officer, Cryoport Inc. and MVE Biological Solutions Robert Stefanovich , Chief Financial Officer, Cryoport Inc. Mark W. Sawicki , Ph.D , Chief Scientific Office, Cryoport, Inc., Chief Executive Officer, Cryopor
Slide 23: Board of Directors
© 2021 Cryoport, Inc. All Rights Reserved Board of Directors 23 Jerrell Shelton, Chairman of the Board Richard Berman, Lead Director Daniel M. Hancock PHOTO PHOTO PHOTO Robert Hariri, PhD, MD PHOTO Ramkumar Mandalam, Ph.D. PHOTO Edward Zecchini PHOTO Ram Jagannath PHOTO
Slide 24: Science. Logistics. Certainty. Thank you!
© 2021 Cryoport, Inc. All Rights Reserved 24 Science. Logistics. Certainty. Thank you!
Slide 25: Supplementary Materials
© 2021 Cryoport, Inc. All Rights Reserved Supplementary Materials
Slide 26: Adjusted EBITDA Reconciliation
© 2021 Cryoport, Inc. All Rights Reserved Adjusted EBITDA Reconciliation 26 Unaudited Pro Forma Combined Adjusted EBITDA Nine Months Ended September 30, 2020 in MM Cryoport CRYOPDP MVE Pro Forma Combined GAAP net income (loss) (21.2) (6.5) 20.6 (7.1) Non - GAAP adjustments to net loss: Depreciation